Gotowa bibliografia na temat „HDAC 3”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „HDAC 3”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "HDAC 3"
Bertos, Nicholas R., Audrey H. Wang i Xiang-Jiao Yang. "Class II histone deacetylases: Structure, function, and regulation". Biochemistry and Cell Biology 79, nr 3 (1.06.2001): 243–52. http://dx.doi.org/10.1139/o01-032.
Pełny tekst źródłaOzawa, Yukiyasu, Masayuki Towatari, Shinobu Tsuzuki, Fumihiko Hayakawa, Takahiro Maeda, Yasuhiko Miyata, Mitsune Tanimoto i Hidehiko Saito. "Histone deacetylase 3 associates with and represses the transcription factor GATA-2". Blood 98, nr 7 (1.10.2001): 2116–23. http://dx.doi.org/10.1182/blood.v98.7.2116.
Pełny tekst źródłaStubbs, Matthew C., Won-Il Kim, Tina Davis, Jun Qi, James Bradner, Andrew L. Kung i Scott A. Armstrong. "Selective Inhibition of HDAC1 and HDAC2 Is a Potential Therapeutic Option for B-All". Blood 116, nr 21 (19.11.2010): 2900. http://dx.doi.org/10.1182/blood.v116.21.2900.2900.
Pełny tekst źródłaVarricchio, Lilian, Carmela Dell'Aversana, Angela Nebbioso, Giovanni Migliaccio, Lucia Altucci, James J. Bieker i Anna Rita F. Migliaccio. "Identification of a New Functional HDAC Complex Composed by HDAC5, GATA1 and EKLF in Human Erythroid Cells". Blood 120, nr 21 (16.11.2012): 979. http://dx.doi.org/10.1182/blood.v120.21.979.979.
Pełny tekst źródłaMigliaccio, Giovanni, Carmela Dell’Aversana, Angela Nebbioso, Elena Alfani, Lilian arricchio, Antonello Mai, Pratima Chaurasia i in. "Ontogenic-Specific Increasesin HDAC1 Activity and Transcription Factor Association During the Maturation of Human Adult Erythroblasts in Vitro." Blood 114, nr 22 (1.11.2009): 1978. http://dx.doi.org/10.1182/blood.v114.22.1978.1978.
Pełny tekst źródłaHess, Lena, Verena Moos, Arnel A. Lauber, Wolfgang Reiter, Michael Schuster, Natascha Hartl, Daniel Lackner i in. "A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation". PLOS Genetics 18, nr 8 (22.08.2022): e1010376. http://dx.doi.org/10.1371/journal.pgen.1010376.
Pełny tekst źródłaKeedy, Kara S., Nancie M. Archin, Adam T. Gates, Amy Espeseth, Daria J. Hazuda i David M. Margolis. "A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression". Journal of Virology 83, nr 10 (11.03.2009): 4749–56. http://dx.doi.org/10.1128/jvi.02585-08.
Pełny tekst źródłaMasselli, Elena, Lilian Varricchio, Barbara Ghinassi, Carolyn Whitsett, Patricia A. Shi i Anna Rita F. Migliaccio. "Class IIa HDAC Inhibitors Reduce HDAC1 Activity by off-Target Effects Which Reduce GATA1 Expression In Human Erythroblasts Expanded Ex-Vivo". Blood 116, nr 21 (19.11.2010): 4780. http://dx.doi.org/10.1182/blood.v116.21.4780.4780.
Pełny tekst źródłaIbrahim, Hany S., Mohamed Abdelsalam, Yanira Zeyn, Matthes Zessin, Al-Hassan M. Mustafa, Marten A. Fischer, Patrik Zeyen i in. "Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity". International Journal of Molecular Sciences 23, nr 1 (29.12.2021): 369. http://dx.doi.org/10.3390/ijms23010369.
Pełny tekst źródłaAngiolilli, Chiara, Pawel A. Kabala, Aleksander M. Grabiec, Iris M. Van Baarsen, Bradley S. Ferguson, Samuel García, Beatriz Malvar Fernandez i in. "Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes". Annals of the Rheumatic Diseases 76, nr 1 (25.07.2016): 277–85. http://dx.doi.org/10.1136/annrheumdis-2015-209064.
Pełny tekst źródłaRozprawy doktorskie na temat "HDAC 3"
Mehdipour, P. "DISSECTING THE ROLE OF HISTONE DEACETYLASE 3 (HDAC3) IN LEUKEMOGENESIS". Doctoral thesis, Università degli Studi di Milano, 2016. http://hdl.handle.net/2434/356617.
Pełny tekst źródłaSaglam, Guluzar. "Synthesis Of Novel Chiral Thiourea Derivatives And Their Applications, Synthesis Of Some Hdac Inhibitors, Addition Of Acyl Phosphonates To Ethylcyanoformate". Master's thesis, METU, 2008. http://etd.lib.metu.edu.tr/upload/3/12609265/index.pdf.
Pełny tekst źródłaPalleti, Janardhan Harish P. "Histone Deacetylase 3 (HDAC3) Regulates Lymphatic Vascular Development". eScholarship@UMMS, 2018. https://escholarship.umassmed.edu/gsbs_diss/1001.
Pełny tekst źródłaGao, Chengzhuo. "Mechanisms Underlying the Regulation and Functions of HDAC7". Case Western Reserve University School of Graduate Studies / OhioLINK, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=case1213890889.
Pełny tekst źródłaMortenson, Jeffrey Benjamin. "Histone Deacetylase 6 (HDAC6) Is Critical for Tumor Cell Survival and Promotes the Pro-Survival Activity of 14-3-3ζ viaDeacetylation of Lysines Within the14-3-3ζ Binding Pocket". BYU ScholarsArchive, 2015. https://scholarsarchive.byu.edu/etd/5568.
Pełny tekst źródłaSargeant, Aaron Matthew. "Preclinical Efficacy and Safety Evaluation of Novel Small-Molecule Targeted Agents for the Prevention and Treatment of Prostate Cancer". The Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=osu1243948876.
Pełny tekst źródłaPolášek, Jaromír. "Implementace protokolu HDLC v síťových simulátorech". Master's thesis, Vysoké učení technické v Brně. Fakulta elektrotechniky a komunikačních technologií, 2018. http://www.nusl.cz/ntk/nusl-377008.
Pełny tekst źródłaWright, Lyndsey Claire. "Analysis of the physiological role of histone deacetylase 3 (HDAC3) and its regulation by inositol phosphates". Thesis, University of Leicester, 2017. http://hdl.handle.net/2381/40315.
Pełny tekst źródłaBONANOMI, MARCELLA. "Normal and pathogenic ataxin-3: biological roles, toxicity and fibrillogenesis". Doctoral thesis, Università degli Studi di Milano-Bicocca, 2014. http://hdl.handle.net/10281/50225.
Pełny tekst źródłaLewandowski, Sara L. "Histone Deacetylase 3 Coordinates Heart Development Through Stage-Specific Roles in Cardiac Progenitor Cells". eScholarship@UMMS, 2012. http://escholarship.umassmed.edu/gsbs_diss/883.
Pełny tekst źródłaCzęści książek na temat "HDAC 3"
Ito, Akihiro, Norikazu Nishino i Minoru Yoshida. "HDAC Inhibitors". W Histone Deacetylases, 271–97. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1385/1-59745-024-3:271.
Pełny tekst źródłaKwon, Paul, Meier Hsu, Dalia Cohen i Peter Atadja. "HDAC Inhibitors". W Histone Deacetylases, 315–32. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1385/1-59745-024-3:315.
Pełny tekst źródłaSchwab, Manfred. "HDAC Inhibitors". W Encyclopedia of Cancer, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_2591-2.
Pełny tekst źródłaUnger, Keith R., Mira Jung i Anatoly Dritschilo. "Histone Deacetylases (HDAC)". W Cancer Therapeutic Targets, 1–11. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-6613-0_10-3.
Pełny tekst źródłaVaquero, Alejandro, Michael Scher i Danny Reinberg. "Biochemistry of Multiprotein HDAC Complexes". W Histone Deacetylases, 23–60. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1385/1-59745-024-3:23.
Pełny tekst źródłaAtadja, Peter W. "HDAC Inhibitors and Cancer Therapy". W Epigenetics and Disease, 175–95. Basel: Springer Basel, 2010. http://dx.doi.org/10.1007/978-3-7643-8989-5_9.
Pełny tekst źródłaKronlage, Mariya, Hugo A. Katus i Johannes Backs. "HDAC Signaling Networks in Heart Failure". W Epigenetics in Cardiac Disease, 191–208. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-41457-7_8.
Pełny tekst źródłaAhmad Ganai, Shabir. "Natural Cyclic Tetrapeptide Histone Deacetylase Inhibitors and Their Optimistic Role in Anticancer Therapy". W Natural HDAC Inhibitors for Epigenetic Combating of Cancer Progression, 23–29. New York: CRC Press, 2022. http://dx.doi.org/10.1201/9781003294863-3.
Pełny tekst źródłaHancock, Wayne W. "Rationale for HDAC Inhibitor Therapy in Autoimmunity and Transplantation". W Histone Deacetylases: the Biology and Clinical Implication, 103–23. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-21631-2_6.
Pełny tekst źródłaTrifunović, Dragana, Eleni Petridou, Antonella Comitato, Valeria Marigo, Marius Ueffing i François Paquet-Durand. "Primary Rod and Cone Degeneration Is Prevented by HDAC Inhibition". W Retinal Degenerative Diseases, 367–73. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-75402-4_45.
Pełny tekst źródłaStreszczenia konferencji na temat "HDAC 3"
Yang, Jiyong, Chintan Chheda, Dina Hauptschein, Latifa Zayou, Josiah Tang, Qiang Wang, Stephen J. Pandol i Mouad Edderkaoui. "Abstract 2735: Targeting HDAC prevents smoking-induced pancreatic cancer metastasis". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2735.
Pełny tekst źródłaYang, Jiyong, Chintan Chheda, Dina Hauptschein, Latifa Zayou, Josiah Tang, Qiang Wang, Stephen J. Pandol i Mouad Edderkaoui. "Abstract 2735: Targeting HDAC prevents smoking-induced pancreatic cancer metastasis". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2735.
Pełny tekst źródłaLi, Mengxing, Suryavathi Viswanadhapalli, Gangadhara Reddy Sareddy, Bindu Santhamma, Hui Yan, Zhenming Xu, Edward Kost i in. "Abstract 4316: Targeting LIFR overcomes HDAC inhibitor resistance in ovarian cancer". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4316.
Pełny tekst źródłaLi, Mengxing, Suryavathi Viswanadhapalli, Gangadhara Reddy Sareddy, Bindu Santhamma, Hui Yan, Zhenming Xu, Edward Kost i in. "Abstract 4316: Targeting LIFR overcomes HDAC inhibitor resistance in ovarian cancer". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4316.
Pełny tekst źródłaNerlakanti, Niveditha, Jeremy McGuire, Diana Yu, Damon R. Reed i Conor C. Lynch. "Abstract 2016: HDAC inhibition significantly reduces primary and lung metastatic osteosarcoma progression". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2016.
Pełny tekst źródłaNerlakanti, Niveditha, Jeremy McGuire, Diana Yu, Damon R. Reed i Conor C. Lynch. "Abstract 2016: HDAC inhibition significantly reduces primary and lung metastatic osteosarcoma progression". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2016.
Pełny tekst źródłaBudka, Justin, Nur Damayanti i Roberto Pili. "Abstract 2366: HDAC inhibition improves immune checkpoint inhibitor efficacy in renal cell carcinoma". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2366.
Pełny tekst źródłaBudka, Justin, Nur Damayanti i Roberto Pili. "Abstract 2366: HDAC inhibition improves immune checkpoint inhibitor efficacy in renal cell carcinoma". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2366.
Pełny tekst źródłaWu, Bocheng. "Abstract 24: Novel STAT3 & HDAC inhibitors that selectively target triple-negative breast cancer cell". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-24.
Pełny tekst źródłaWu, Bocheng. "Abstract 24: Novel STAT3 & HDAC inhibitors that selectively target triple-negative breast cancer cell". W Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-24.
Pełny tekst źródłaRaporty organizacyjne na temat "HDAC 3"
Pignataro, C., i M. Townsley. High-Level Data Link Control (HDLC) Frames over Layer 2 Tunneling Protocol, Version 3 (L2TPv3). RFC Editor, luty 2006. http://dx.doi.org/10.17487/rfc4349.
Pełny tekst źródłaGur, Amit, Edward Buckler, Joseph Burger, Yaakov Tadmor i Iftach Klapp. Characterization of genetic variation and yield heterosis in Cucumis melo. United States Department of Agriculture, styczeń 2016. http://dx.doi.org/10.32747/2016.7600047.bard.
Pełny tekst źródła